Guide

Hair shedding on GLP-1s

By Juvenate editorial · October 19, 2026

More hair in the shower a few months into semaglutide or tirzepatide is a common worry. The labels record it. Dermatology reviews mostly describe a temporary shed tied to weight loss, not a new kind of baldness.

What people notice

The usual report is diffuse shedding: more strands on the pillow, in the brush, or around the drain, and a ponytail that feels thinner. It often shows up weeks to a few months after weight starts coming off, not on the first injection. The scalp itself usually looks normal. Round bald patches, a painful scalp, or broken hairs at the root are a different problem and belong with a clinician, not with a nickname.

“Ozempic hair,” like “Ozempic face,” is a nickname. Ozempic and Wegovy are semaglutide. Mounjaro and Zepbound are tirzepatide. The shedding story is about the class and the weight loss, not one logo.

What the labels actually counted

In the adult weight-management trials summarized on the Wegovy label, hair loss was listed in 3% of people on semaglutide 2.4 mg once weekly and 1% on placebo. A separate FDA labeling note on the same program is a little more precise: in a pool of studies, hair loss was reported in 3.3% on Wegovy 2.4 mg and 1% on placebo, and it was more common in women (4%) than in men (0.9%). The label ties those reports to weight reduction.

The Zepbound label lists hair loss in 5% of people on 5 mg, 4% on 10 mg, and 5% on 15 mg, against 1% on placebo. Again the label says the reports were associated with weight reduction. In the pooled studies, 7.1% of women on Zepbound reported hair loss, compared with 0.5% of men. No one on Zepbound in that pool stopped the drug because of hair loss. One person on placebo did.

A 2026 meta-analysis in Diabetes Research and Clinical Practice pooled interventional studies and found hair loss reported more often on a GLP-1 medicine than on placebo (risk ratio about 3.3, with a wide confidence interval from about 1.4 to 7.4). The single-arm event rate in that paper was 3.9%. Those figures come from how trials record an adverse event. They are not a dermatologist’s exam, and they are not a forecast for one person.

Clinic impressions run higher than trial checkboxes. A Cleveland Clinic explainer quotes an endocrinologist estimating that roughly a quarter to a third of people using these medicines for weight loss notice some shedding. That is one clinician’s experience, not a trial endpoint.

The pattern has a name

Dermatologists call the common pattern telogen effluvium. Most scalp hairs are growing. A body stress can push a larger share into the resting phase. Those hairs shed weeks to months later, which is why the timing feels delayed. Cleveland Clinic’s patient page describes telogen effluvium as temporary thinning after a major stress or a change in the body, and says hair often grows back over three to six months once the trigger settles. That is the usual course of this pattern. It is not a promise that every person on a GLP-1 will follow it.

A 2026 review in the Cleveland Clinic Journal of Medicine lists the familiar triggers: illness, surgery, childbirth, strong emotional stress, some medicines, and diet changes aimed at fast weight loss, including eating too little protein or too few calories. Low iron, zinc, or vitamin D are often discussed; the same review says the evidence that they cause the shed is still thin. The practical point is simpler. If appetite has collapsed, the meal that remains has to do more work.

Cleveland Clinic’s endocrinology explainer puts the GLP-1 version in that same frame. The drug is not described there as a direct toxin to the follicle. Rapid weight loss is the stress, the same pattern clinicians already knew from bariatric surgery. A 2026 review in JAAD Reviews, from the American Academy of Dermatology’s review journal, is more cautious about mechanism. It says a link is suspected, causality is not settled, and results differ by drug. Proposed contributors include fast weight loss, a lower calorie intake, and micronutrient gaps. Shedding, when it is reported, often follows the telogen pattern and may ease when the trigger eases. The authors also note that weight loss can unmask ordinary patterned hair loss that was already underway. Those are different diagnoses, and this page cannot tell them apart.

What this page will not claim

It will not say the medicine “causes baldness.” The labels show a higher rate of hair-loss reports than placebo, clustered with weight loss, and more often in women. That is an association recorded in trials. It is not proof of a permanent, scarring alopecia, and it is not a reason this site sells a serum. There are no affiliate links here. A product that promises to stop GLP-1 shedding is marketing until a source says otherwise.

It will also not tell you to stop a prescribed medicine. Hair is not a vital organ. The condition the medicine was prescribed for may be. Only the prescriber can weigh those against each other.

What usually helps while you wait

The supports in the clinic explainers are unglamorous. Eat enough that the deficit is not a crash, and give protein a real place on the plate. The protein guide covers how researchers talk about ranges, without setting a gram target. Be gentler with the hair you still have: looser styles, less heat, less pulling on wet hair. That does not restart a follicle. It does keep breakage from being mistaken for a new shed.

Pace is a prescriber question. Clinicians who write about this often say a slower loss is less of a shock to the hair cycle. Whether your dose should change is not a decision for an article.

See a dermatologist or the prescriber if the shed is patchy, the scalp hurts or scales, eyebrows or body hair are falling too, or the thinning is still accelerating after several months of steady weight. Bring a photo timeline if you have one. Mention iron history, thyroid history, recent illness, and how little you are actually eating. A 2026 JAAD Reviews paper notes that specialists sometimes discuss follicle-directed treatments. That is a clinic conversation. This page does not recommend a drug, a dose, or a procedure.

Sources

1. Novo Nordisk. Wegovy (semaglutide) prescribing information, adverse reactions table. DailyMed.
2. U.S. Food and Drug Administration. Wegovy safety-related labeling changes, hair loss note. FDA SrLC.
3. Eli Lilly. Zepbound (tirzepatide) prescribing information, hair loss section. DailyMed.
4. Cheng PL, Chang HC. GLP-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. PubMed 42155605.
5. Cleveland Clinic. Telogen effluvium. my.clevelandclinic.org.
6. Cleveland Clinic. Can Ozempic cause hair loss? health.clevelandclinic.org.
7. Shedding: an updated guide to a common cause of hair loss. Cleveland Clinic Journal of Medicine. CCJM.
8. Spindler A, et al. GLP-1 receptor agonists and hair loss: current evidence and potential mechanisms. JAAD Reviews. 2026;9:200-211. JAAD Reviews.